| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Laboratory of Epidemiology, Demography and Biometry (Drs. Strozyk and Launer), National Institute on Aging, NIH, Bethesda, MD; Department of Clinical Neuroscience (Dr. Blennow), Sahlgren’s University Hospital, Mölndal, Sweden; and Pacific Health Research Institute (Dr. White), Honolulu, HI.
Address correspondence and reprint requests to Dr. D. Strozyk, LEDB/NIA/NIH, Gateway Bldg 3C-309, 7201 Wisconsin Avenue, Bethesda, MD 20892; e-mail: strozykd{at}mail.nih.gov
Objective: To investigate the relationship of amyloid neuropathology to postmortem CSF Aß 42 levels in an autopsy sample of Japanese American men from the population-based Honolulu–Asia Aging Study.
Methods: In 1991, participants were assessed and diagnosed with dementia (including subtype) based on published criteria. At death CSF was obtained from the ventricles. Neuritic plaques (NP) and diffuse plaques in areas of the neocortex and hippocampus were examined using Bielschowsky silver stains. Cerebral amyloid angiopathy (CAA) was measured by immunostaining for ß4 amyloid in cerebral vessels in the neocortex. Neuropathologically confirmed AD was diagnosed using Consortium to Establish a Registry for Alzheimer’s Disease criteria. In 155 autopsy samples, log transformed linear regression models were used to examine the association of NP and CAA to Aß 42 levels, controlling for clinical dementia severity, time between diagnosis and death, age at death, brain weight, hours between death and collection of CSF, education, and APOE genotype.
Results: Higher numbers of NP in the neocortex (p trend = 0.001) and in the hippocampus (p trend = 0.03) were strongly associated with lower levels of Aß 42. Individuals with CAA had lower Aß 42 levels (ß coefficient = -0.48; 95% CI -0.9, -0.1). Compared to participants with a diagnosis of clinical dementia, those with pathologically confirmed AD had lower Aß 42 levels (ß coefficient = -0.74; 95% CI -1.4, -0.1).
Conclusion: The current study suggests that lower Aß 42 levels reflect neuropathologic processes implicated in amyloid-related pathologies, such as NP and CAA.
This article has been cited by other articles:
|
|
 |
|
  H. Zetterberg, U. Andreasson, O. Hansson, G. Wu, S. Sankaranarayanan, M. E. Andersson, P. Buchhave, E. Londos, R. M. Umek, L. Minthon, et al. Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease Arch Neurol, August 1, 2008; 65(8): 1102 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bian, J. C. Van Swieten, S. Leight, L. Massimo, E. Wood, M. Forman, P. Moore, I. de Koning, C. M. Clark, S. Rosso, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology Neurology, May 6, 2008; 70(19_Part_2): 1827 - 1835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ewers, Z. Zhong, K. Burger, A. Wallin, K. Blennow, S. J. Teipel, Y. Shen, and H. Hampel Increased CSF-BACE 1 activity is associated with ApoE-{varepsilon}4 genotype in subjects with mild cognitive impairment and Alzheimer's disease Brain, May 1, 2008; 131(5): 1252 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Engelborghs, K. Sleegers, P. Cras, N. Brouwers, S. Serneels, E. De Leenheir, J.-J. Martin, E. Vanmechelen, C. Van Broeckhoven, and P. P. De Deyn No association of CSF biomarkers with APOE{varepsilon}4, plaque and tangle burden in definite Alzheimer's disease Brain, September 1, 2007; 130(9): 2320 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R Gustafson, I. Skoog, L. Rosengren, H. Zetterberg, and K. Blennow Cerebrospinal fluid {beta}-amyloid 1-42 concentration may predict cognitive decline in older women J. Neurol. Neurosurg. Psychiatry, May 1, 2007; 78(5): 461 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Buerger, M. Ewers, T. Pirttila, R. Zinkowski, I. Alafuzoff, S. J. Teipel, J. DeBernardis, D. Kerkman, C. McCulloch, H. Soininen, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain, November 1, 2006; 129(11): 3035 - 3041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Stenset, L. Johnsen, D. Kocot, A. Negaard, A. Skinningsrud, P. Gulbrandsen, A. Wallin, and T. Fladby Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42. Neurology, September 12, 2006; 67(5): 830 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Peskind, G. Li, J. Shofer, J. F. Quinn, J. A. Kaye, C. M. Clark, M. R. Farlow, C. DeCarli, M. A. Raskind, G. D. Schellenberg, et al. Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid beta-Amyloid 42 in Adults With Normal Cognition. Arch Neurol, July 1, 2006; 63(7): 936 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. M. Olde Rikkert, W. M. van der Flier, F. E. deLeeuw, M. Verbeek, R. W. M. M. Jansen, F. Verhey, and P. Scheltens Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia Arch Neurol, January 1, 2006; 63(1): 144 - 146. [Full Text] [PDF]
|
|
|
|
|
|
W M van der Flier and P Scheltens Use of laboratory and imaging investigations in dementia J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(suppl_5): v45 - v52. [Full Text] [PDF]
|
|
|
|
|
|
M. Moonis, J. M. Swearer, M. P. E. Dayaw, P. St. George-Hyslop, E. Rogaeva, T. Kawarai, and D. A. Pollen Familial Alzheimer disease: Decreases in CSF A{beta}42 levels precede cognitive decline Neurology, July 26, 2005; 65(2): 323 - 325. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
